Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai’s Cancer Strategy Bears Early IO Combo Fruit

Executive Summary

Interim data from a Phase Ib/II of a combination of Eisai’s halichondrin Halaven with Merck & Co’s immuno-oncology product Keytruda suggest it could represent a novel treatment regimen in patients with metastatic triple negative breast cancer, in an early vindication for the Japanese company’s strategy of expanding its oncology franchise.

You may also be interested in...



Lenvatinib Measures Up To Sorafenib In HCC But Prospects Limited?

Eisai's lenvatinib has hit its primary endpoint in a large Phase III trial comparing it with sorafenib in first-line hepatocellular carcinoma, paving the way for regulatory filings in the important indication and strengthening the firm's expansion strategy in oncology.

Eisai hopes for Halaven bump with combo

Merck & Co And Eisai Link Up For Combo Cancer Studies

Merck & Co and Eisai have signed a deal to assess various combinations of their immuno-oncology drugs in clinical trials. Merck's anti-PD-1 therapy, pembrolizumab (Keytruda) is to be tested in combination with Eisai's lenvatinib (Lenvima) and eribulin (Halaven) in multiple clinical studies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel